Kestrel Therapeutics Inc. has patented new GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.

Incyte Corp. has described GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, inflammatory and immunological disorders.

Betta Pharmaceuticals Co. Ltd. has identified GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.

Incyte Corp. has disclosed GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, as well as autoimmune and inflammatory disorders.

Scientists at Hyperway Pharmaceutical Co. Ltd. and Shenzhen Hyperway Pharmaceuticals Co. Ltd. have divulged GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, LEOPARD and Noonan syndromes.

Suzhou Zion Pharma Technology Co. Ltd. has identified GTPase KRAS G12D or G13D mutant and/or KRAS inhibitors reported to be useful for the treatment of cancer.

Tyligand Bioscience Ltd. has patented GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.

Mirati Therapeutics Inc. has divulged GTPase KRAS (G12S mutant) and/or GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Gilead Sciences Inc. has discovered GTPase KRAS and its mutant inhibitors reported to be useful for the treatment of cancer.

Erasca Inc. has disclosed GTPase KRAS (G12D and G12V) mutant inhibitors reported to be useful for the treatment of cancer.